Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values

BACKGROUND: Metastatic pancreatic cancer (mPC) and its treatments significantly impact health-related quality of life (HRQoL). POLO, a randomized, double-blind, placebo-controlled phase 3 trial evaluated the efficacy of olaparib as maintenance therapy in germline BRCA mutated mPC patients who had no...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Suvina, Joo, Seongjung, Nolte, Sandra, Yoo, Hyun Kyoo, Patel, Nikunj, Byrnes, Hilary F., Costa-Cabral, Sara, Johnson, Colin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123808/
https://www.ncbi.nlm.nih.gov/pubmed/35596182
http://dx.doi.org/10.1186/s12885-022-09661-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123808/
https://www.ncbi.nlm.nih.gov/pubmed/35596182
http://dx.doi.org/10.1186/s12885-022-09661-7

Ejemplares similares